Integrin Alpha10 Patent for Aggressive Cancer Treatment

The European Patent Office published patent EP3956360A1 titled 'Integrin Alpha10 and Aggressive Cancer Forms' on April 8, 2026. The patent application filed by Targinta AB covers compositions including anti-integrin alpha10 antibodies and methods for treating aggressive cancer forms. The patent designates 37 European states including AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

For pharmaceutical companies and biotechnology researchers, this patent establishes intellectual property protection for integrin alpha10 targeting in cancer therapeutics within the designated European territory. Parties developing similar integrin alpha10 antibody therapies or cancer treatment methods should evaluate potential patent overlap and consider freedom-to-operate analysis for European markets covered by this grant.